NeuroMetrix, Inc.
NURO · NASDAQ Capital Market · USD
4,58USD
+0,22 (+5,05 %)Stand 1. Mai, 20:00
Kennzahlen
- Eröffnung
- 4,36
- Vortag
- 4,36
- Tagesspanne
- 4,3304 – 4,69
- 52 Wochen
- 2,66 – 4,73
- Volumen
- 35.587
- Ø Volumen
- 5301
- Börsenwert
- 9,43 Mio. $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 1,8
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
NeuroMetrix, Inc. is a healthcare company focused on creating, manufacturing, and distributing medical devices that stimulate and evaluate nerve function for both diagnostic and therapeutic applications. These products are available across a wide geographical area, including the United States, Europe, Japan, China, the Middle East, and Mexico. The company's core offerings include DPNCheck, a nerve conduction test used to identify and assess peripheral neuropathies such as diabetic peripheral neuropathy; Quell, a wearable device engineered for the relief and management of persistent pain; and the ADVANCE system, a dedicated platform for performing comprehensive nerve conduction studies. NeuroMetrix supplies its advanced solutions to a diverse clientele, encompassing managed care organizations, primary care providers, specialists like endocrinologists, podiatrists, various surgeons (including orthopedic and hand surgeons), occupational health practitioners, and neurology, pain medicine, and physical medicine and rehabilitation experts. Incorporated in 1996, the company's headquarters are located in Woburn, Massachusetts.
- CEO
- Shai N. Gozani
- Mitarbeitende
- 13
- Hauptsitz
- Woburn, MA, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 22. Juli 2004
- Website
- neurometrix.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.